Literature DB >> 14507338

Tumour necrosis and microvascular proliferation are associated with 9p deletion and CDKN2A alterations in 1p/19q-deleted oligodendrogliomas.

C Godfraind1, E Rousseau, M-M Ruchoux, F Scaravilli, M Vikkula.   

Abstract

A subset of oligodendrogliomas and oligoastrocytomas has been associated with 1p/19q deletion. Subsequently, this genetic alteration was linked to chemosensitivity and classic histology of oligodendrogliomas. Tumoural progression includes deletions of 9p, 10q and alterations of CDKN2A. However, these (epi)genetic changes have not been associated with specific histological features. In a series of 45 gliomas including oligodendrogliomas, oligoastrocytomas and astrocytomas, deletions of chromosomal regions implied in these tumours (1p, 9p, 10, 17p13, 19q and 22) were looked for by microsatellite analysis. Tumours that were deleted for 1p and 19q were selected. Subsequently, presence of deletions in the other studied regions, (epi)genetic changes in p14ARF, CDKN2A and CDKN2B, as well as histological features, were associated to these tumours. 1p/19q deletion was observed in 22 tumours. Twenty-one of them presented regions of classic histology of oligodendroglioma. A deletion of 9p was found in eight of them, always in association with tumour necrosis and/or microvascular proliferation. In addition, (epi)genetic alterations of CDKN2A were observed in 71% of these tumours. Presence of regions of classic histology of oligodendroglioma in a tumour sample is predictive of 1p/19q deletions. Necrosis and/or microvascular proliferation are signs of an additional 9p deletion. Finally, as CDKN2A (epi)genetic alterations were found in 71% of the 1p/19q/9p-deleted oligodendrogliomas, CDKN2A may have a role in oligodendroglioma-associated microvascular proliferation.

Entities:  

Mesh:

Year:  2003        PMID: 14507338     DOI: 10.1046/j.1365-2990.2003.00484.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  15 in total

1.  The presence of necrosis and/or microvascular proliferation does not influence survival of patients with anaplastic oligodendroglial tumours: review of 98 patients.

Authors:  Sarah F Smith; Judy M Simpson; Janice A Brewer; Lali H S Sekhon; Michael T Biggs; Raymond J Cook; Nicholas S Little
Journal:  J Neurooncol       Date:  2006-06-23       Impact factor: 4.130

Review 2.  Molecular epidemiology of primary brain tumors.

Authors:  Jun Gu; Yanhong Liu; Athanassios P Kyritsis; Melissa L Bondy
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

3.  Tumor vascular leakiness and blood volume estimates in oligodendrogliomas using perfusion CT: an analysis of perfusion parameters helping further characterize genetic subtypes as well as differentiate from astroglial tumors.

Authors:  Jayant Narang; Rajan Jain; Lisa Scarpace; Sona Saksena; Lonni R Schultz; Jack P Rock; Mark Rosenblum; Suresh C Patel; Tom Mikkelsen
Journal:  J Neurooncol       Date:  2010-08-01       Impact factor: 4.130

4.  Chromosomal defects track tumor subpopulations and change in progression in oligodendroglioma.

Authors:  David W Nauen; Andrew Guajardo; Lisa Haley; Kerry Powell; Peter C Burger; Christopher D Gocke
Journal:  Converg Sci Phys Oncol       Date:  2015-06-16

5.  Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment.

Authors:  Silke Wemmert; Ralf Ketter; Jörg Rahnenführer; Niko Beerenwinkel; Martin Strowitzki; Wolfgang Feiden; Christian Hartmann; Thomas Lengauer; Florian Stockhammer; Klaus D Zang; Eckart Meese; Wolf-Ingo Steudel; Andreas von Deimling; Steffi Urbschat
Journal:  Neoplasia       Date:  2005-10       Impact factor: 5.715

6.  Histogram analysis of MR imaging-derived cerebral blood volume maps: combined glioma grading and identification of low-grade oligodendroglial subtypes.

Authors:  K E Emblem; D Scheie; P Due-Tonnessen; B Nedregaard; T Nome; J K Hald; K Beiske; T R Meling; A Bjornerud
Journal:  AJNR Am J Neuroradiol       Date:  2008-06-26       Impact factor: 3.825

7.  Assessment of tumor angiogenesis as a prognostic factor of survival in patients with oligodendroglioma.

Authors:  H Quon; A Hasbini; J Cougnard; L Djafari; C Lacroix; B Abdulkarim
Journal:  J Neurooncol       Date:  2009-07-19       Impact factor: 4.130

Review 8.  Therapeutic targets in the ARF tumor suppressor pathway.

Authors:  Anthony J Saporita; Leonard B Maggi; Anthony J Apicelli; Jason D Weber
Journal:  Curr Med Chem       Date:  2007       Impact factor: 4.530

9.  Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression.

Authors:  German Reyes-Botero; Caroline Dehais; Ahmed Idbaih; Nadine Martin-Duverneuil; Marion Lahutte; Catherine Carpentier; Eric Letouzé; Olivier Chinot; Hugues Loiseau; Jerome Honnorat; Carole Ramirez; Elisabeth Moyal; Dominique Figarella-Branger; François Ducray
Journal:  Neuro Oncol       Date:  2013-12-18       Impact factor: 13.029

10.  Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations.

Authors:  Dominique Figarella-Branger; Karima Mokhtari; Caroline Dehais; Anne Jouvet; Emmanuelle Uro-Coste; Carole Colin; Catherine Carpentier; Fabien Forest; Claude-Alain Maurage; Jean-Michel Vignaud; Marc Polivka; Emmanuelle Lechapt-Zalcman; Sandrine Eimer; Gabriel Viennet; Isabelle Quintin-Roué; Marie-Hélène Aubriot-Lorton; Marie-Danièle Diebold; Delphine Loussouarn; Catherine Lacroix; Valérie Rigau; Annie Laquerrière; Fanny Vandenbos; Sophie Michalak; Henri Sevestre; Michel Peoch; François Labrousse; Christo Christov; Jean-Louis Kemeny; Marie-Pierre Chenard; Danchristian Chiforeanu; François Ducray; Ahmed Idbaih
Journal:  Neuro Oncol       Date:  2014-04-09       Impact factor: 13.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.